Clinical Trial

A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study is to assess adverse events, change in body weight and pharmacokinetics in adult participants with obesity receiving ABBV-295 subcutaneous injections or matching placebo.
Protocol Amendment History 4 changes
notable Enrollment increased: 48 -> 80 participants 2026-08-08
minor Trial arms changed: 4 -> 8 2026-08-08
notable Primary completion pushed: 2026-10 -> 2027-03 2026-08-08
minor Completion pushed: 2026-10 -> 2027-03 2026-08-08
Trial Details
NCT Number NCT07291232
Lead Sponsor AbbVie
Conditions Obesity
Enrollment 80 participants
Start Date 2025-11-19
Primary Completion 2027-03 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2026-08-07